A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy. (2021)
Attributed to:
Understanding and Ameliorating perturbed signalling and pathogenesis in FSHD
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41417-020-00225-0
PubMed Identifier: 32973362
Publication URI: http://europepmc.org/abstract/MED/32973362
Type: Journal Article/Review
Volume: 28
Parent Publication: Cancer gene therapy
Issue: 5
ISSN: 0929-1903